Zhang J, et al. - Researchers examined the long-term outcome of direct-acting antiviral agents (DAAs) therapy in a Chinese cohort of HCV-infected kidney transplant recipients. In this single-center and retrospective study, 26 kidney transplant (KTX) recipients were separated into a KTX-hemodialysis Group, a DAA-KTX Group and a KTX-DAA Group. Target not detected within 12 weeks was defined as on-treatment response. They defined sustained virologic response 48, 96 as HCV-RNA negativity 48, 96 weeks after treatment cessation, respectively. Genotypes 1b and 2a were the only ones identified at the researchers’ center, with the main one being 1b. HCV-infected kidney transplant recipients treated with DAAs had good tolerability during long-term follow-up and it was persistently effective. Findings strongly emphasize performing regular monitoring of renal function in patients with preexisting impaired renal function who receive DAA regimens; frequent monitoring of the trough calcineurin inhibitor levels was also recommended.